Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06986382) titled 'Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease' on May 20.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Stanford University
Condition:
Crohn Disease
Intervention:
Device: CliniMACS(R) TCR a/ß Reagent Kit and CliniMACS(R) CD19 System
Drug: Prednisone/Methylprenisolone
Drug: Palifermin
Drug: ATG
Drug:...